| Name | Title | Contact Details |
|---|
Meditrina, a startup company located in Cupertino, CA, was founded in 2016, and developed the Aveta™ System, a single-use Hysteroscope and Resecting Device, with an all-inclusive HD Visualization and Fluid Management system. A new office Hysteroscopy system which can also be used in the clinic or hospital operating room (OR), for diagnostic or therapeutic Hysteroscopy procedures. Procedures include: Diagnostic Hysteroscopy, biopsy, and soft tissue removal such as, fibroids, polyps, and/or retained products of conception (RPOC).
KOTYS is a Powell, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aurillion is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Volpara Health Technologies Limited is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara software helps clinicians better understand their patients and administrators better understand their practices. Volpara Health Technologies Limited (formerly Matakina Technology Limited) is a research, development, and manufacturing company based in Wellington, New Zealand. With a diverse research team led by internationally recognized experts in medical physics, as well as proprietary medical imaging technology covered by multiple patents and trademarks, we apply science to the solving of clinical problems around the world. Volpara Health Technologies Limited holds certification to ISO13485 and is a US FDA–registered establishment whose products are listed accordingly. In addition, our products hold CE Marking under European Medical Device Directive 93/42/EEC. Volpara Solutions Limited is our wholly owned sales and marketing subsidiary.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.